"We found that H3K27M-glioma primarily contain cells that resemble oligodendrocyte precursor cells (OPC-like), whereas more differentiated malignant cells are a minority. OPC-like cells exhibit greater proliferation and tumor-propagating potential than their more differentiated counterparts and are at least in part sustained by PDGFRA signaling."
PDGFRA is a receptor tyrosine kinase (like EGFR). No PDGFRA inhibitors have been specifically approved for brain tumors, but inhibitors have been approved for other types of cancers. Approved PDGFRA inhibiting drugs include imatinib, nilotinib, sorafenib, and dasatinib.